Thymosin Alpha-1

Amino Acid Sequence:

Ser‑Asp‑Ala‑Ala‑Val‑Asp‑Thr‑Ser‑Ser‑Glu‑Ile‑Thr‑Thr‑Lys‑Asp‑Leu‑Lys‑Glu‑Lys‑Lys‑Glu‑Val‑Val‑Glu‑Glu‑Ala‑Glu‑Asn

Chemical Formula:

C₁₂₉H₂₁₅N₃₃O₅₅

CAS Registry Number:

62304‑98‑7

• Immune enhancement & T‑cell activation

• Viral‑infection adjunct therapy

• Oncology immune support

• Sepsis & critical‑care immune modulation

• Vaccine adjuvant applications

• Autoimmune & immune‑dysregulation disorders

• Chronic‑disease immune restoration

Innate & Adaptive Immune Activation

• Promotes T‑cell maturation and differentiation

• Enhances dendritic‑cell function and antigen presentation

• Activates Toll‑like receptors (TLR2, TLR9) to coordinate innate immunity

Cytokine & Immune‑Balance Modulation

• Supports balanced Th1/Th2 cytokine profiles

• Improves immune coordination under stress or immunosuppression

Pathogen Defense & Immune Restoration

• Enhances antiviral responses

• Supports immune recovery in chronic disease or compromised states

Thymosin Alpha‑1 is approved in multiple countries for immune‑related indications, including viral infections and oncology‑adjunct therapy. In the United States, it is not FDA‑approved, though it has a long history of clinical use internationally and a strong safety profile. Its extensive research base and global therapeutic adoption continue to drive interest in immune‑modulating peptide research.

1. Goldstein, A. L., & Badamchian, M. (2004). Thymosin Alpha‑1: biological activities, applications, and therapeutic potential. Annals of the New York Academy of Sciences, 1028, 1–13.

2. Garaci, E. (2000). Thymosin Alpha‑1 in the treatment of chronic viral infections and cancer. International Journal of Immunopharmacology, 22(12), 1067–1076.

3. Romani, L., et al. (2004). Thymosin Alpha‑1 activates dendritic cells and enhances T‑cell immunity. Journal of Experimental Medicine, 200(10), 139–148.

4. Matteucci, C., et al. (2013). Immunomodulatory effects of Thymosin Alpha‑1 in viral diseases. Expert Opinion on Biological Therapy, 13(1), 113–128.

5. Liu, Y., et al. (2016). Thymosin Alpha‑1 as an immune‑restorative agent in sepsis. Critical Care Medicine, 44(6), e304–e313.

6. Pica, F., & Garaci, E. (2012). Thymosin Alpha‑1: a peptide for immune regulation and therapy. Expert Opinion on Biological Therapy, 12(3), 341–348.

7. King, R., et al. (2015). Thymosin Alpha‑1 as a vaccine adjuvant: mechanisms and clinical potential. Human Vaccines & Immunotherapeutics, 11(3), 681–689.

8. Wu, J., et al. (2018). Thymosin Alpha‑1 improves immune function in immunocompromised patients: a meta‑analysis. Clinical Therapeutics, 40(7), 1073–1085.

CURRENT BATCH being tested